LAS VEGAS, Dec. 9, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced a newly published study from the Mayo Clinic reinforces the critical role of the "longevity protein" -Klotho in vascular health and aging. The research, appearing in the Journal of the American Heart Association, demonstrates a strong association between declining -Klotho ...